AnHeart Therapeutics
Dr. Tony Tong is a Principal of Decheng Capital and has been with the firm since May 2014. He has an interest in diverse sectors within the China healthcare industry. He currently serves on the boards of AnHeart Therapeutics, CardiMED, Insight Lifetech and LYNK Pharmaceuticals.
Prior to joining Decheng Capital, Dr. Tong was a Vice President at Mingly China Growth Fund (MCGF), focusing on evaluating investment opportunities in the healthcare sector and serving on the boards of Yocaly (acquired by Lepu Medical), Family of Health (partially acquired by Sunshine Insurance), Sonicmed and Baifendian Technology. From 2009 to 2012, Dr. Tong was a Senior Investment Associate at Yifang Ventures, a venture capital investment and asset management firm founded by Dr. Eric Xu, the Co-founder of Baidu.com. Dr. Tong received his Ph.D. in Biochemistry and Molecular Biology from the Institute of Biophysics of the Chinese Academy of Science, a BS degree in Life Science from the University of Science and Technology of China, and a second BS degree in Economics from Peking University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.